Ionis Pharmaceuticals (IONS) Operating Margin (2009 - 2026)

Ionis Pharmaceuticals' Operating Margin history runs 18 years deep, the most recent figure standing at 38.18% for Q2 2026.

• In Q2 2026, Operating Margin fell 6911.0% year-over-year to 38.18%; the TTM figure through Jun 2026 stood at 87.66% (down 5943.0% YoY), while the FY2025 annual figure was 40.45%, up 2693.0% from the prior year.
• Operating Margin for Q2 2026 stood at 38.18%, up from 234.85% in the prior quarter.
• The five-year high for Operating Margin was 30.93% in Q2 2025, with the low at 234.85% in Q1 2026.
• The 5-year median for Operating Margin is 75.68% (2023), against an average of 77.27%.
• The sharpest annual moves came in 2022 and 2023: Operating Margin tumbled 18709 bps in 2022, then jumped 13507 bps in 2023.
• Ionis Pharmaceuticals' Operating Margin stood at 136.95% in 2022, then surged by 99 bps to 1.89% in 2023, then plunged by 2493 bps to 48.91% in 2024, then sank by 116 bps to 105.47% in 2025, then surged by 64 bps to 38.18% in 2026.
• Business Quant data shows IONS's Operating Margin at 38.18% in Q2 2026, 234.85% in Q1 2026, and 105.47% in Q4 2025.